Breaking News, Collaborations & Alliances

Fujifilm Cellular Dynamics, Opsis Therapeutics and BlueRock Therapeutics Form Agreement

BlueRock licenses an iPSC-derived photoreceptor cell therapy for human retinal diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSC), and Opsis Therapeutics, a joint venture of Fujifilm Cellular Dynamics and co-founder David Gamm (MD, PhD) focusing on developing cell therapies for patients with ocular diseases, formed an agreement granting BlueRock Therapeutics an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases. BlueRock Ther...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters